The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don't just curb their desire to eat; for some, they also lead them to drink ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Sure, who wouldn’t want to lose a few pounds? But what’s really driving Hollywood’s latest trend is the drug’s seemingly miraculous side benefits ...

We recently compiled a list of the 11 Best Stocks To Invest In For Grandchildren. In this article, we are going to take a ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...